Page 170 - Eceptor News Today

A new study found that the Omicron variant contains a number of mutations that decrease neutralizing antibody activity and immune escape.

Independent teams from Texas Biomedical Research Institute and the Medical College of Wisconsin have published two papers in Science Translational Medicine identifying how the only approved drug to treat schistosomiasis, a widespread parasitic worm infection, works on the molecular level.

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

Many studies have indicated that bats are significant reservoirs of innumerable viruses, such as influenza, coronaviruses, and rabies. These studies have also reported that bats predominantly remain asymptomatic or develop mild diseases during viral infections caused by henipaviruses, Ebola virus, coronaviruses, etc.

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

Can the COVID-19 delta variant evade vaccine-induced immunity? We spoke to Professor Brian J. Willett from the University of Glasgow to find out.

Drugs we take like prednisone can weaken our bones and so can aging, and scientists working to prevent both have some of the first evidence that the best target may not be the logical one.

Results from a new study could be crucial in studying the molecular and biochemical basis of SARS-CoV-2 infection at a more granular level and help in strategizing therapeutic solutions to treat and manage COVID-19 effectively.

In a new study, a team of researchers developed a genetic assay to evaluate several clade 2 and clade 3 receptor-binding domains (RBD) of spike (S) protein sequences of genus sarbecovirus.